Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914966 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE
A Phase 4 study, sponsored by Shire.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00914966 is a Phase 4 study that has completed, run by Shire. The registered enrollment target is 20 participants.
The verdict
NCT00914966, a Phase 4 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The objectives of the study were: 1. To assess the safety and tolerability of escalating doses of CINRYZE. 2. To assess the effect of an escalating dose algorithm for CINRYZE on hereditary angioedema (HAE) attack rates. 3. To assess the immunogenicity of CINRYZE.
Interventions
- BIOLOGICAL C1 inhibitor (human) [C1 INH]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-08-31 |
| Est. Completion | 2012-05-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00914966
The ClinicalTrials.gov registry entry for NCT00914966 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which C1 inhibitor (human) [C1 INH] is the first listed.
NCT00914966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00914966 about?
NCT00914966 is a clinical study titled "A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE". The objectives of the study were: 1. To assess the safety and tolerability of escalating doses of CINRYZE. 2. To assess the effect of an escalating dose algorithm for CINRYZE on hereditary angioedema (HAE) attack rates. 3. To assess the immunogenicity of CINRYZE.
What is the current status of trial NCT00914966?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2009-08-31. Estimated completion is 2012-05-24.
What interventions are being tested in trial NCT00914966?
The interventions under investigation include: C1 inhibitor (human) [C1 INH] (BIOLOGICAL).
Who is sponsoring clinical trial NCT00914966?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.